MYOG +50% in pre-market. Doesn’t seem justified given that this is only one of two pivotal trials in PAH and this is not even MYOG’s most important drug.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”